Dimensional Fund Advisors LP Sells 2,063 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Dimensional Fund Advisors LP cut its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 8.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,717 shares of the company’s stock after selling 2,063 shares during the period. Dimensional Fund Advisors LP’s holdings in EyePoint Pharmaceuticals were worth $169,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of the stock. Franklin Resources Inc. raised its holdings in EyePoint Pharmaceuticals by 3.1% during the 4th quarter. Franklin Resources Inc. now owns 4,137,567 shares of the company’s stock valued at $30,825,000 after buying an additional 125,519 shares during the period. Vanguard Group Inc. lifted its holdings in shares of EyePoint Pharmaceuticals by 24.8% in the 4th quarter. Vanguard Group Inc. now owns 3,803,227 shares of the company’s stock worth $28,334,000 after acquiring an additional 755,045 shares during the last quarter. Federated Hermes Inc. boosted its stake in shares of EyePoint Pharmaceuticals by 92.7% during the 4th quarter. Federated Hermes Inc. now owns 3,707,445 shares of the company’s stock worth $27,620,000 after purchasing an additional 1,783,765 shares during the period. Geode Capital Management LLC grew its holdings in EyePoint Pharmaceuticals by 28.3% during the 4th quarter. Geode Capital Management LLC now owns 1,538,902 shares of the company’s stock valued at $11,467,000 after purchasing an additional 339,846 shares during the last quarter. Finally, Finepoint Capital LP raised its position in EyePoint Pharmaceuticals by 57.1% in the 4th quarter. Finepoint Capital LP now owns 1,111,104 shares of the company’s stock worth $8,278,000 after purchasing an additional 403,700 shares during the period. 99.41% of the stock is owned by institutional investors.

EyePoint Pharmaceuticals Trading Up 7.2%

EYPT opened at $6.13 on Friday. EyePoint Pharmaceuticals, Inc. has a 12-month low of $3.91 and a 12-month high of $13.99. The business’s fifty day simple moving average is $5.91 and its 200-day simple moving average is $7.33. The company has a market capitalization of $421.81 million, a price-to-earnings ratio of -3.07 and a beta of 1.58.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.65) EPS for the quarter, meeting the consensus estimate of ($0.65). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. The business had revenue of $24.50 million during the quarter, compared to analyst estimates of $8.84 million. On average, equities research analysts predict that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on EYPT shares. Mizuho cut their target price on EyePoint Pharmaceuticals from $30.00 to $26.00 and set an “outperform” rating on the stock in a research note on Friday. StockNews.com raised EyePoint Pharmaceuticals to a “sell” rating in a research report on Friday, March 14th. Chardan Capital decreased their target price on EyePoint Pharmaceuticals from $33.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, May 8th. Finally, HC Wainwright reissued a “buy” rating and set a $22.00 target price on shares of EyePoint Pharmaceuticals in a research note on Thursday, March 6th. One research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.38.

EyePoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.